RE:RE:RE:As a basis of comparison...There's also this article, which is more comprehensive:
Non-muscle-invasive bladder cancer: An overview of potential new treatment options Aim
This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Gurin (BCG)-nave, BCG-recurrent, and BCG-unresponsive patient populations are also described, e.g., those involving immune checkpoint inhibitors, targeted therapies, other chemotherapy regimens, vaccines, and viral- or bacterial-based treatments. Finally, a brief overview of enhanced cystoscopy and drug delivery systems for the diagnosis and treatment of NMIBC is provided.
Background
A global shortage of access to BCG is affecting the management of BCG-nave and BCG-recurrent/unresponsive NMIBC; hence, there is an urgent need to assist patients and urologists to enhance the treatment of this disease.
Methods
Searches of ClinicalTrials.gov, PubMed, and Google Scholar were conducted. Published guidance and conference proceedings from major congresses were reviewed.
Conclusion
Treatment strategies for NMIBC are generally consistent across guidelines. Several novel therapies have demonstrated promising antitumor activity in clinical trials, including in high-risk or BCG-unresponsive disease. The detection, diagnosis, surveillance, and treatment of NMIBC have also been improved through enhanced disease detection.
DJDawg wrote:
On the subject of keytruda...is that it these days? I know vicineum is not looking too promising at the moment. So the current state for BCG unresponsive cases is....
- ketruda (or an investigation trial such as for TLD1433)
- cystectomy after that?
Just curious if there were any other products vying for the next line therapy?